Clinical trial · Interventional
Radiofrequency Ablation Combined With Recombinant Human Adenovirus Type 5 in the Treatment of Hepatocellular Carcinoma.
Radiofrequency Ablation Combined With Local Injection of Recombinant Human Adenovirus Type 5 in the Treatment of Hepatocellular Carcinoma:A Multicenter Prospective Randomized Controlled Trial.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary reason for recurrence of hepatocellular carcinoma after radiofrequency ablation (RFA) is the micro-metastatic lesion that has not been ablated and inactivated in the transitional area.Some clinical trials have confirmed that H101(recombinant human adenovirus type 5 injection) has selective oncolysis in a variety of solid tumors.However, there are no reports that H101 which is injected during surgery can improve the efficacy of RFA in liver cancer at present.Therefore,We used a multicenter prospective randomized controlled study as the main method to prospectively compare the short-term and long-term efficacy of RFA combined with H101 group and traditional RFA group in the treatment of small liver cancer (single lesion , diameter less than or equal to 3cm，to evaluate the value of RFA combined with H101 injection in reducing the postoperative recurrence rate of small hepatocellular carcinoma, and to provide a reliable evidence-based medical basis for the selection of treatment methods for small hepatocellular carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| H101 | Drug | — | UNRESOLVED |
| RFA | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- RFA combined with H101 group
- description
- The experimental group was RFA combined H101.H101 has oncolysis in HCC after RFA and reduce tumor recurrence.
- interventionNames
- Drug: H101
- Procedure: RFA
- type
- OTHER
- label
- Conventional RFA group
- description
- The standard control group was the conventional RFA.Using RFA for the treatment of small HCC.The efficacy was compared with that of the experimental group combined with H101.
- interventionNames
- Procedure: RFA
Primary outcomes (1)
- measure
- Tumor-free survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. The patients understand the content and significance of the study and we obtain a written informed consent from them. 2. The patients' gender are not limited and are between the ages of 18 and 75. 3. Liver function of Child-Pugh Class A or B;The retention rate of indocyanine green for 15 minutes is less than or equal to 20%. 4. The ECOG score is 0. 5. The diagnosis was a single hepatocellular carcinoma with a diameter of no more than 3cm. 6. There were no other related diseases affecting RFA treatment. Exclusion Criteria: 1. There are tumor emboli in the large vessels of the liver;distant metastasis of HCC. 2. The patient has or has had a history of refractory ascites,hepatic encephalopathy, or esophageal varices hemorrhage. 3. The patient was complicated with other malignant tumors. 4. The patient has severe cardiac, renal and other organ dysfunction. 5. In addition to viral hepatitis, there are other active infectious diseases.
References
Publications (0)
Data not yet available